EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: Study protocol for a randomized controlled trial

Trials

Volumn 14, Issue 1, 2013, Pages

  Timsit, Jean François ^a,f,g   Azoulay, Elie ^b,f   Cornet, Muriel ^a   Gangneux, Jean Pierre ^c   Jullien, Vincent ^d,e   Vésin, Aurélien ^a,f   Schir, Edith ^a   Wolff, Michel ^g  

^a UNIV GRENOBLE ALPES   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d INSERM   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f Outcomerea Organization   (France)

^g BICHAT HOSPITAL   (France)

Author keywords

Candidemia; Colonization; Invasive candidiasis; Micafungin; Nosocomial sepsis

Indexed keywords

MICAFUNGIN; PLACEBO;

ANTIFUNGAL RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CULTURE; BLOOD SAMPLING; CONTROLLED STUDY; FOLLOW UP; FUNGAL COLONIZATION; HOSPITAL INFECTION; HUMAN; INVASIVE CANDIDIASIS; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL;

ANTIFUNGAL AGENTS; CANDIDEMIA; CLINICAL PROTOCOLS; CROSS INFECTION; DOUBLE-BLIND METHOD; ECHINOCANDINS; HUMANS; INTENSIVE CARE UNITS; LIPOPEPTIDES; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDIES;

EID: 84887962698     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-399     Document Type: Article

References (45)

1. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001, 33:177-186. 10.1086/321811, 11418877.
2. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, Pfaller M, Edwards JE, Jarvis W, Dawson J, Wenzel RP. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999, 29:253-258. 10.1086/520194, 10476721.
3. Garrouste-Orgeas M, Timsit JF, Tafflet M, Misset B, Zahar JR, Soufir L, Lazard T, Jamali S, Mourvillier B, Cohen Y, et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis 2006, 42:1118-1126. 10.1086/500318, 16575729.
4. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a six-year validated, population-based model. Clin Infect Dis 1997, 24:1068-1078. 10.1086/513640, 9195059.
5. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317. 10.1086/421946, 15306996.
6. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. International study of the prevalence and outcomes of infection in intensive care units. Jama 2009, 302:2323-2329. 10.1001/jama.2009.1754, 19952319.
7. Charles PE, Dalle F, Aube H, Doise JM, Quenot JP, Aho LS, Chavanet P, Blettery B. Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med 2005, 31:393-400. 10.1007/s00134-005-2571-y, 15711782.
8. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994, 220:751-758. 10.1097/00000658-199412000-00008, 1234477, 7986142.
9. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003, 3:685-702. 10.1016/S1473-3099(03)00801-6, 14592598.
10. Leon C, Alvarez-Lerma F, Ruiz-Santana S, Leon MA, Nolla J, Jorda R, Saavedra P, Palomar M. Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study. Eur J Clin Microbiol Infect Dis 2009, 28:233-242. 10.1007/s10096-008-0618-z, 18758831.
11. Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care 2011, 1:37. 10.1186/2110-5820-1-37, 3224461, 21906271.
12. Leon C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C, Balasini C, Utande-Vazquez A, de Molina FJG, Blasco-Navalproto MA, et al. Usefulness of the 'Candida score' for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009, 37:1624-1633. 10.1097/CCM.0b013e31819daa14, 19325481.
13. Ostrosky-Zeichner L. Issues in the design and interpretation of antifungal drug trials in the critically ill. Curr Opin Infect Dis 2009, 22:564-567. 10.1097/QCO.0b013e328331fc5f, 19726983.
14. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31. 10.1086/504810, 16758414.
15. Grim SA, Berger K, Teng C, Gupta S, Layden JE, Janda WM, Clark NM. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother 2012, 67:707-714. 10.1093/jac/dkr511, 22184469.
16. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008, 36:2967-2972. 10.1097/CCM.0b013e31818b3477, 18824910.
17. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645. 10.1128/AAC.49.9.3640-3645.2005, 1195428, 16127033.
18. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006, 34:857-863. 10.1097/01.CCM.0000201897.78123.44, 16505666.
19. Guery BP, Arendrup MC, Auzinger G, Azoulay E, Borges Sa M, Johnson EM, Muller E, Putensen C, Rotstein C, Sganga G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I Epidemiology and diagnosis. Intensive Care Med 2009, 35:55-62. 10.1007/s00134-008-1338-7, 18972101.
20. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Calandra T, Glauser MP, Tauber MG, Pittet D. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991 to 2000. Clin Infect Dis 2004, 38:311-320. 10.1086/380637, 14727199.
21. San Miguel LG, Cobo J, Otheo E, Sanchez-Sousa A, Abraira V, Moreno S. Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol 2005, 26:548-552. 10.1086/502582, 16018430.
22. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 2005, 31:1479-1487. 10.1007/s00134-005-2794-y, 16172847.
23. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002, 28:1708-1717. 10.1007/s00134-002-1540-y, 12447512.
24. Jacobs S, Price Evans DA, Tariq M, Al Omar NF. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit Care Med 2003, 31:1938-1946. 10.1097/01.CCM.0000074724.71242.88, 12847386.
25. Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, Lipsett PA. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001, 233:542-548. 10.1097/00000658-200104000-00010, 1421284, 11303137.
26. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006, 57:628-638. 10.1093/jac/dki491, 16459344.
27. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005, 33:1928-1935. Quiz 1936, 10.1097/01.CCM.0000178352.14703.49, 16148461.
28. Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, Boillot A. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004, 32:2443-2449. 10.1097/01.CCM.0000147726.62304.7F, 15599149.
29. Schuster MG, Edwards JE, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, Slotman G, Panzer H, Biswas P, Rex JH. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008, 149:83-90. 10.7326/0003-4819-149-2-200807150-00004, 18626047.
30. Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, Hennequin C, Martin C. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006, 34:646-652. 10.1097/01.CCM.0000201889.39443.D2, 16505648.
31. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. 10.1086/596757, 19191635.
32. Azoulay E, Garrouste M, Goldgran-Toledano D, Adrie C, Max A, Vesin A, Francais A, Zahar JR, Cohen Y, Allaouchiche B, et al. Increased nonbeneficial care in patients spending their birthday in the ICU. Intensive Care Med 2012, 38:1169-1176. 10.1007/s00134-012-2510-7, 22323081.
33. Laupland KB, Zahar JR, Adrie C, Minet C, Vesin A, Goldgran-Toledano D, Azoulay E, Garrouste-Orgeas M, Cohen Y, Schwebel C, et al. Severe hypothermia increases the risk for intensive care unit-acquired infection. Clin Infect Dis 2012, 54:1064-1070. 10.1093/cid/cir1033, 22291110.
34. Machin D, Campbell M, Fayers P, Pinol A. Sample Size Tables for Clinical Studies 1997, Blackwell science: Malden, MA, USA, 2.
35. Azoulay E, Dupont H, Tabah A, Lortholary O, Stahl JP, Francais A, Martin C, Guidet B, Timsit JF. Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med 2012, 40:813-822. 10.1097/CCM.0b013e318236f297, 22297630.
36. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011, 39:665-670. 10.1097/CCM.0b013e318206c1ca, 21169817.
37. Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, Maviglia R, Fadda G, Sanguinetti M, Antonelli M. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-beta-D-glucan assay, Candida score, and colonization index. Critical Care (London, England) 2011, 15:R249.
38. Held J, Kohlberger I, Rappold E, Busse Grawitz A, Hacker G. Comparison of (1 → 3)-beta-D-glucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia. J Clin Microbiol 2013, 51:1158-1164. 10.1128/JCM.02473-12, 3666776, 23363830.
39. Sims CR, Jaijakul S, Mohr J, Rodriguez J, Finkelman M, Ostrosky-Zeichner L. Correlation of clinical outcomes with beta-glucan levels in patients with invasive candidiasis. J Clin Microbiol 2012, 50:2104-2106. 10.1128/JCM.00773-12, 3372136, 22461680.
40. Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1 → 3)-beta-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis 2012, 55:521-526. 10.1093/cid/cis456, 22573851.
41. Clancy CJ, Nguyen MH. Finding the 'missing 50%' of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013, 56:1284-1292. 10.1093/cid/cit006, 23315320.
42. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011, 55:532-538. 10.1128/AAC.01128-10, 3028765, 21078946.
43. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012, 50:1199-1203. 10.1128/JCM.06112-11, 3318516, 22278842.
44. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, Bretagne S, Dromer F, Lortholary O. Candida spp. with acquired echinocandin resistance, France, 2004 to 2010. Emerg Infect Dis 2012, 18:86-90. 10.3201/eid1801.110556, 3310099, 22257484.
45. Fournier P, Schwebel C, Maubon D, Vesin A, Lebeau B, Foroni L, Hamidfar-Roy R, Cornet M, Timsit JF, Pelloux H. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J Antimicrob Chemother 2011, 66:2880-2886. 10.1093/jac/dkr394, 21980066.